Amgen Inc: (NASD: AMGN)
$101.50
2.42 (2.44%)
Volume 3,283,906
Jun 18 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Brokerage Recommendations
| Current ABR | 2.18 |
| ABR (Last week) | 2.18 |
| # of Recs in ABR | 22 |
| Average Target Price | $110.69 |
| LT Growth Rate | 8.40% |
| Industry | MED-BIOMED/GENE |
| Industry Rank by ABR | 105 of 265 |
| Current Quarter EPS Est: | 1.68 |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
105 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 9.00 | 9.00 | 10.00 | 11.00 | 12.00 |
| Buy | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| Hold | 13.00 | 13.00 | 13.00 | 14.00 | 13.00 |
| Sell | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Strong Sell | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| ABR | 2.18 | 2.18 | 2.13 | 2.12 | 2.04 |
Analyst Upgrades/Downgrades
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
